The DMD survey panel comprises 5,000 individuals working within retail pharmacies, primarily pharmacy managers or senior level staff, and 1,300 acute-care pharmacists working within hospitals. The ImpactRx panel, meanwhile, consists of a cross-section of 100,000 medical professionals, with particular specialties in primary care, general medicine and individuals working within retail pharmacies.

Through the new partnerships, Cint will offer healthcare organisations access to the panels via its OpinionHub platform.

Bo Mattsson, chief executive of Cint (pictured), said: “Obtaining an informed opinion from this audience, whether it is a dermatologist, a pain specialist or an optometrist, can be a challenging process, due to the pressures and time constraints on these individuals, and traditional market research methods such as focus groups can be ineffective. These new partnerships with DMD and ImpactRx mean specific groups of experts can be targeted entirely online and, therefore, they are able to provide their responses and opinions within a timeframe that suits them.”